Quetiapin

Research use only, not for human use.

Quetiapine is indicated for the treatment of schizophrenia as well as for the treatment of acute manic episodes associated with bipolar I disorder.

Quetiapine is indicated for the treatment of schizophrenia as well as for the treatment of acute manic episodes associated with bipolar I disorder. The antipsychotic effect of quetiapine is thought by some to be mediated through antagonist activity at dopamine and serotonin receptors. Specifically the D1 and D2 dopamine, the alpha 1 adrenoreceptor and alpha 2 adrenoreceptor, and 5-HT1A and 5-HT2 serotonin receptor subtypes are antagonized. Quetiapine also has an antagonistic effect on the histamine H1 receptor. (In Vitro):Quetiapine (<100?μM; 24?hours) has no significant effect on cell viabilities.Quetiapine (10?μM) inhibits NO release, which increased by LPS (0.1-100 ng/mL) in concentration-dependent manner.Quetiapine (10?μM) also inhibits TNF-α synthesis.(In Vivo):Quetiapine (10?mg/kg/day; ingested) can alleviate the recruitment and activation of microglia and promote myelin repair in Cuprizone (CPZ)-induced chronic mouse model of demyelination.

——

Animal Model:C57BL/6 mice Dosage:10?mg/kg/day Administration:Ingested Result:Significantly increased in optical density of myelin basic protein (MBP) staining compared to Veh group.

——

Endocrinology/Hormones

5-HT Receptor

5-HT| mAChR| Adrenergic Receptor| Dopamine| H1 receptor

Neurological Disease

——

111974-69-7

383.51

C21H25N3O2S

>98% (HPLC)

DMSO: 36 mg/mL;Water: <1 mg/mL

OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12

——

(-20℃)

With Ice Pack

≥ 2 years